Supreme Court Blocks Apotex Glaucoma Drug Invalidity Appeal

Law360, New York (March 26, 2012, 1:55 PM EDT) -- The U.S. Supreme Court on Monday refused to consider Apotex Inc.'s appeal of a lower court's ruling that Allergan Inc.'s glaucoma eyedrop formulation patents are not obvious in a suit accusing Apotex of infringing Allergan's patents through its generic drug application.

The high court denied Apotex's petition for a writ of certiorari to review the Federal Circuit's ruling last year that upheld the validity of four separate Allergan glaucoma treatment patents in an appeal of its infringement case against Apotex and fellow generics maker Exela PharmSci...
To view the full article, register now.